The clinical value of progesterone receptor expression in luminal breast cancer: A study of a large cohort with long-term follow-up.
Ayat Gamal LashenMichael S TossNigel P MonganAndrew R GreenEmad A RakhaPublished in: Cancer (2023)
In this study, we have established an optimal approach to determine the prognostic value of progesterone receptor expression in estrogen receptor-positive breast cancer patients. To do this, the levels of progesterone receptor were measured in a large cohort of estrogen receptor-positive breast cancer patients. We have refined the definition of progesterone receptor positivity in estrogen receptor-positive breast cancer. We show that progesterone receptor expression adds prognostic and predictive value of endocrine therapy in estrogen receptor-positive breast cancer patients, and our results show that the absence of progesterone receptor is associated with poorer outcomes independent of tumor grade, size, node stage, and Ki67 expression.
Keyphrases
- estrogen receptor
- positive breast cancer
- end stage renal disease
- newly diagnosed
- ejection fraction
- chronic kidney disease
- prognostic factors
- poor prognosis
- type diabetes
- peritoneal dialysis
- squamous cell carcinoma
- mesenchymal stem cells
- lymph node
- bone marrow
- young adults
- neoadjuvant chemotherapy
- weight loss
- rectal cancer
- locally advanced
- childhood cancer
- chemotherapy induced